Post by uniQure

Today we announced promising interim data from the Phase I/II trial of our #genetherapy AMT-130. The encouraging update shows early signs of potential clinical benefit and supportive trends in NfL, a key marker of neuronal damage. Patients treated with either dose of AMT-130 appear to have largely preserved function and are trending favorably to natural disease course at up to 24 months. We believe these interim results provide early hope for patients suffering from #huntingtonsdisease. https://lnkd.in/eG4Fd3R2